Olema director receives 29,500-share stock option grant

Olema Pharmaceuticals director Ian T. Clark received a new stock option grant.

Rhea-AI Filing Summary

Olema Pharmaceuticals director Ian T. Clark received a new stock option grant. The award covers 29,500 shares of common stock at an exercise price of $9.51 per share and expires on June 18, 2036. The option vests in 12 equal monthly installments starting on June 18, 2026, with all remaining unvested shares vesting earlier on the date of Olema’s next annual stockholder meeting if it occurs sooner, in each case subject to his continued service.

Insider Trade Summary

Grant/Award: 29,500 shares

Grant/Award 1 txn

Insider CLARK IAN T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	29,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 29,500 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Option grant size: 29,500 shares Exercise price: $9.51 per share Expiration date: June 18, 2036 +2 more

5 metrics

Option grant size 29,500 shares Stock option covering common stock reported on Form 4

Exercise price $9.51 per share Strike price for the 29,500-share stock option

Expiration date June 18, 2036 Option term end date for the reported grant

Vesting schedule length 12 monthly installments Equal monthly vesting starting June 18, 2026

Vesting start date June 18, 2026 First vesting date for the option grant

Key Terms

Stock Option (right to buy), exercise price, vest, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "9.5100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The shares subject to the option vest in a series of 12 successive equal monthly installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"Such shares vest in full on the date of the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Olema Pharmaceuticals (OLMA) director Ian T. Clark report on this Form 4?

Ian T. Clark reported receiving a stock option grant for 29,500 Olema Pharmaceuticals shares. The option is a compensation award, not an open-market purchase or sale, and gives him the right to buy common stock at a fixed exercise price.

How many Olema Pharmaceuticals (OLMA) shares are covered by the new option grant?

The option grant covers 29,500 shares of Olema Pharmaceuticals common stock. These are underlying shares that may be acquired in the future upon exercise of the option, subject to vesting and Clark’s continued service with the company.

What is the exercise price of Ian T. Clark’s Olema Pharmaceuticals (OLMA) stock option?

The option has an exercise price of $9.51 per share. This means Clark can buy Olema Pharmaceuticals common stock at $9.51 for each of the 29,500 underlying shares once they vest and before the option’s expiration date.

When do Ian T. Clark’s Olema Pharmaceuticals (OLMA) options vest?

The 29,500-share option vests in 12 equal monthly installments beginning on June 18, 2026. Any remaining unvested portion then vests in full on the date of Olema’s next annual stockholder meeting, assuming Clark continues to serve through each vesting date.

When do the newly granted Olema Pharmaceuticals (OLMA) stock options expire?

The stock options reported on the Form 4 expire on June 18, 2036. Clark must exercise any vested portion of the 29,500-share grant before that expiration date; otherwise, the right to purchase those shares will lapse.

Does this Olema Pharmaceuticals (OLMA) Form 4 show any stock being bought or sold on the market?

No open-market buy or sell transactions are reported. The Form 4 only shows a grant of a stock option award, which is a derivative security giving Clark future rights to acquire shares, rather than an immediate market trade in Olema stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 05:26 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CLARK IAN T

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CALIFORNIA 94103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$9.51	06/18/2026		A		29,500		(1)	06/18/2036	Common Stock	29,500	$0	29,500	D

Explanation of Responses:

1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Shawnte Mitchell, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)